HEALTH

Acetaminophen products to undergo changes following advisory committee’s votes

BY Michael Johnsen

NEW YORK While the impetus for this multiple advisory committee meeting and the Food and Drug Administration’s working group that first examined this issue had been in the works long before the Obama administration took office — and consequently the new FDA took hold — there has been some concern that an overly zealous agency is placing any shred of safety concern ahead of consumer access — no matter how miniscule that safety risk may be.

 

In that regard, and so long as the FDA acts on the recommendations made by its advisory committees as is typical, the outcome of last week’s meeting isn’t as bad as it could have been. Combination APAP products are likely not to be recalled, which is good news beyond just McNeil Consumer and its Tylenol franchise. Also what-would-have-been-costly pack-size limitations, such as limiting the number of daily doses merchandised in each SKU to no more than three appears to also be off the table based on committee recommendations.

 

 

Those two actions would have been costly to manufacturers and retailers alike, especially as that would have resulted in a potential wholesale recall of products already in the supply chain. And if manufacturers are able to sell-through the current maximum dosing of 1,000 mg, then the overall cost to the industry will be relatively less.

 

 

 

The problem that remains, however, is public perception around the safety of acetaminophen, which by all accounts is safe when used as directed. And that’s going to be a problem in the coming weeks as the story of the committee meeting makes its way through the news cycle, and again when the FDA announces any changes it will make regarding the sale of OTC and prescription-only acetaminophen products in the coming months.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

LIVE FROM MARKETPLACE: Kicking the habit with Nicorette

BY Drug Store News Team

PITTSBURGH GlaxoSmithKline plans to launch the first recently FDA-approved innovation into the smoking cessation category in seven years.

With a planned launch of Aug. 31, the product differentiators include a handy, convenience dispenser for discreet on-the-go use and a smaller lozenge that dissolves three-times faster than the classic lozenge and delivers the entire dose of nicotine within some 10 minutes.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

LIVE FROM MARKETPLACE: Osteo-Bi Flex adds vitamin D

BY Drug Store News Team

RONKONKAMA, N.Y. What do you get when you cross one of the hottest bone/joint supplements on the market with one of the hottest dietary supplement categories? Osteo-Bi Flex Plus Vitamin D, that’s what. Not only is favorable vitamin-D press hitting the airwaves just about every other day, but it happens to be good for bone health, too. A 2007 study found that higher vitamin D levels helped maintain and improve bone density in post-menopausal women, for example.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?